GT Biopharma, Inc. (NASDAQ:GTBP) Short Interest Down 62.4% in March

GT Biopharma, Inc. (NASDAQ:GTBP) was the recipient of a significant drop in short interest during the month of March. As of March 15th, there was short interest totalling 94,200 shares, a drop of 62.4% from the February 28th total of 250,300 shares. Based on an average daily trading volume, of 852,200 shares, the days-to-cover ratio is currently 0.1 days. Approximately 4.2% of the company’s stock are short sold.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Roth Capital raised shares of GT Biopharma to a “strong-buy” rating in a research report on Monday, December 2nd. Roth Mkm started coverage on GT Biopharma in a report on Monday, December 2nd. They set a “buy” rating and a $11.00 price objective for the company.

GT Biopharma Stock Up 4.3 %

NASDAQ:GTBP traded up $0.10 during trading hours on Friday, hitting $2.40. 15,611 shares of the company traded hands, compared to its average volume of 581,285. The company has a market cap of $6.09 million, a PE ratio of -0.34 and a beta of 0.59. The firm’s 50-day simple moving average is $2.29 and its 200-day simple moving average is $2.50. GT Biopharma has a one year low of $1.72 and a one year high of $10.66.

GT Biopharma Company Profile

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.